Vaxcyte Revenue and Competitors

Location

#3574

Growjo Ranking

Biotech

Industry

Estimated Revenue & Valuation

  • Vaxcyte's estimated annual revenue is currently $17.1M per year.(i)
  • Vaxcyte's estimated revenue per employee is $52,786
  • Vaxcyte's total funding is $281M.
  • Vaxcyte's current valuation is $1B. (January 2022)

Employee Data

  • Vaxcyte has 323 Employees.(i)
  • Vaxcyte grew their employee count by 54% last year.

Vaxcyte's People

NameTitleEmail/Phone
1
SVP, General Counsel and Corporate SecretaryReveal Email/Phone
2
SVP, Nonclinical, Clinical Serology, ImmunoassaysReveal Email/Phone
3
VP Corporate Communications & Investor RelationsReveal Email/Phone
4
VP Analytical Development and QCReveal Email/Phone
5
Executive Assistant To CEO and Chief Financial Officer/PresidentReveal Email/Phone
6
VP, IT and FacilitiesReveal Email/Phone
7
VP Research and FounderReveal Email/Phone
8
SVP, Development and ManufacturingReveal Email/Phone
9
SVP Commercial Manufacturing and Supply ChainReveal Email/Phone
10
Project Director, Program ManagementReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.4M57-8%$53MN/A
#2
$21.2M137-26%$110MN/A
#3
$0.9M60%N/AN/A
#4
$2.3M1515%N/AN/A
#5
$1.6M10-17%N/AN/A
#6
$0.7M950%N/AN/A
#7
$11.5M74-12%N/AN/A
#8
$0.4M27510%$236.7MN/A
#9
$4M51-74%$160MN/A
#10
$2.3M1515%N/AN/A
Add Company

What Is Vaxcyte?

Vaxcyte, formerly known as SutroVax, is a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide. The Company's cell-free protein synthesis platform, comprising the XpressCFTM platform, exclusively licensed from Sutro Biopharma, Inc., together with Vaxcyte's proprietary know-how, enables the design and production of protein carriers and antigens, the critical building blocks of vaccines, in ways that the Company believes conventional vaccine technologies currently cannot. In addition to its pneumococcal conjugate vaccines in development, VAX-24 and VAX-XP, Vaxcyte is leveraging its proprietary platform to advance other novel vaccines, including a prophylactic vaccine to prevent Group A Strep infections (VAX-A1) and a therapeutic vaccine to treat periodontal disease (VAX-PG).

keywords:N/A

$281M

Total Funding

323

Number of Employees

$17.1M

Revenue (est)

54%

Employee Growth %

$1B

Valuation

N/A

Accelerator

Vaxcyte News

2022-04-17 - Vaxcyte, Inc. (NASDAQ:PCVX) COO Sells $67144.00 in Stock

Vaxcyte, Inc. (NASDAQ:PCVX – Get Rating) COO Jim Wassil sold 2,800 shares of the stock in a transaction that occurred on Monday, April 18th.

2022-04-17 - Insider Selling: Vaxcyte, Inc. (NASDAQ:PCVX) CEO Sells ...

Get Vaxcyte alerts: On Monday, March 21st, Grant Pickering sold 14,288 shares of Vaxcyte stock. The stock was sold at...

2022-04-06 - Vaxcyte Doses First Participants in Phase 2 Portion of ...

SAN CARLOS, Calif., April 04, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$71M32716%$384.5M
#2
$116.1M379N/AN/A
#3
$79.5M4245%N/A
#4
$143.3M4688%N/A
#5
$90M506-1%$61.9M